Back to search

Article

Patient and Healthcare Professional Experience with Fixed-Dose Subcutaneous Pertuzumab and Trastuzumab (PHESGO) in a High-Volume Oncology Center in Vietnam: A Real-World Study from a Resource-Constrained Setting

2026-08-31

Abstract excerpt

<title>Abstract</title> <p> Background Fixed-dose subcutaneous pertuzumab and trastuzumab (PHESGO®) has been shown to provide clinical efficacy comparable to intravenous (IV) administration while substantially reducing treatment time. However, real-world evidence regarding patient and healthcare professional (HCP) satisfaction remains limited, particularly in low- and middle-income countries (LMICs), where opti...

Identifiers and source

Literature Corpus work
cb92c6e6-34ec-513e-a549-acb5026b1a50
DOI
10.21203/rs.3.rs-10326326/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Patient and Healthcare Professional Experience with Fixed-Dose Subcutaneous Pertuzumab and Trastuzumab (PHESGO) in a High-Volume Oncology Center in Vietnam: A Real-World Study from a Resource-Constrained SettingDOI 10.21203/rs.3.rs-10326326/v1
Select a neighboring publication to make it the new centre.